FDA bars critic from review panel of Biogen's controversial Alzheimer's drug ...Middle East

Mayo Clinic neurologist Dr. David Knopman confirmed on Monday that he was recused from the scheduled meeting of outside advisors to the FDA. Expert advisory panels often play an important role ahead of FDA approval decisions, although the agency is not required to take their advice. Knopman, who said he was recused because of his involvement in conducting clinical trials of aducanumab, has been a vocal critic of the drug, including in a paper published on Sunday in the journal Alzheimer's & Dementia.

Hence then, the article about fda bars critic from review panel of biogen 39 s controversial alzheimer 39 s drug was published today ( Monday 02/11/2020 - 09:30 PM ) and is available on Yahoo ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( FDA bars critic from review panel of Biogen's controversial Alzheimer's drug )

Also on site :

• CNN Tests the Waters With a Creator-Driven Concept
• SAG-AFTRA Launches Verticals Agreement for Microdramas
• 98% of homes that used government insulation scheme need mould repairs